Intuniv

Guanfacine, the active ingredient in Intuniv, is an alpha‑2 adrenergic agonist presented as an extended‑release tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents. GNH USA supplies Intuniv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Intuniv is a non‑stimulant medication that targets the ADHD symptom pathway in pediatric patients. - Attention deficit hyperactivity disorder (ADHD) in children and adolescents: improves attention, reduces hyperactivity and impulsivity.

Intuniv may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Headache: mild to moderate cranial pain. - Dry mouth: reduced salivation leading to a dry sensation. - Stomach discomfort: nausea, abdominal pain or dyspepsia. - Dizziness: light‑headed feeling, especially when standing quickly.

Serious or Rare Side Effects: - Low blood pressure: symptomatic hypotension, sometimes with fainting. - Slow heart rate: bradycardia that may require monitoring. - Depression or mood changes: emergence of depressive symptoms. - Liver enzyme elevation: abnormal liver function tests. - Allergic reactions: rash, itching, swelling or difficulty breathing.

Before initiating Intuniv, clinicians should evaluate several safety considerations. - Cardiovascular assessment: check blood pressure and heart rate baseline. - Concomitant medications: review other agents that affect blood pressure or heart rate. - History of depression: monitor mood changes during therapy. - Liver function: assess hepatic status if pre‑existing liver disease is present. - Pregnancy: category C; weigh potential benefits against risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Intuniv can interact with other drugs that influence cardiovascular or central nervous system function.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase guanfacine levels. - Other antihypertensives: additive blood‑pressure‑lowering effect.

Moderate Interactions (Monitor Closely):\n- CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation. - Stimulant ADHD medications: may counteract blood‑pressure effects. - Antidepressants (e.g., tricyclics): potential for additive hypotensive effects.